Wegovy pill UK statistics 2026

What changed in June and July 2026

The MHRA approval announcement for Wegovy tablets gives June 11, 2026 as the UK approval date. The Guardian report on UK Wegovy tablet launch placed private high street and online sales in early July 2026. Approval and private sale should be read as separate milestones.

The BMJ note on private UK Wegovy pill access gives the NHS position. It says the pill can be bought privately from high street pharmacies and online chemists, but is not yet accessible on the NHS because cost-effectiveness evaluation still has to run through NICE. Private availability can arrive before NHS funding decisions.

Who can be prescribed Wegovy tablets in the UK

The MHRA approval announcement for Wegovy tablets and the Wegovy 1.5 mg tablets SmPC describe the same adult population: obesity with BMI 30 or above, or overweight with BMI 27 to 30 and at least one weight-related comorbidity. Private pharmacy copy may shorten that to one BMI threshold, so the label is the better source for eligibility.

The NHS semaglutide medicine page and the NHS England Wegovy specialist-service page show why private eligibility and NHS access still feel different. NHS England still describes Wegovy for obesity as a specialist-service prescription and still describes it as once weekly in that public access page, which is a signal that the NHS pathway has not yet caught up to the private tablet launch.

How the morning tablet routine works

The Wegovy 1.5 mg tablets SmPC is clear about the daily sequence. Take the tablet on an empty stomach after at least 8 hours of fasting, swallow it whole with up to half a glass of water, and then wait at least 30 minutes before food, drink, or other oral medicines. The NHS semaglutide medicine page repeats the same timing pattern in plain language.

The tablet removes needles, pens, and fridge storage. It also creates a fixed morning routine that some people will find harder than a once-weekly injection. A medication record helps because problems usually show up first in timing, meals, symptoms, and missed doses.

The Wegovy pill tracker and GLP-1 tracker are useful when you need one place for those details. The fields that matter most are fasting window, pill time, the 30-minute wait, meals, hydration, symptoms, and whether the tablet was skipped or delayed.

What the current trial numbers actually show

EMA reported average body-weight loss of 13.61% with Wegovy tablets versus 2.18% with placebo in the cited 64-week phase 3 trial. EMA also said 76.3% of people taking the tablet lost at least 5% of body weight versus 30.5% with placebo. Those results belong with the regulator source, trial duration, and study population.

The Wegovy 1.5 mg tablets SmPC fills in the tolerability picture. In the oral programme, nausea was reported in 46.6% of semaglutide-tablet patients, vomiting in 30.9%, diarrhoea in 17.6%, and constipation in 20.1%. The same SmPC also says those gastrointestinal events were reported most often during dose escalation, which is exactly when people are also adjusting to the fasting routine.

What private UK prices look like now

UK private prices differ by seller and dose. Boots weight loss treatment page lists Wegovy tablets from £99.00. Superdrug Wegovy pill page lists the product in stock from £99.00. Pharmacy2U Wegovy tablets page lists 1.5 mg at £109.99 and 4 mg at £119.99, while 9 mg and 25 mg were still marked as coming soon on July 13, 2026.

Broader private-price guides show why a starting-price chart is not enough. Healthcount reports launch pricing from roughly £99 to £154 a month for the 1.5 mg starter dose, with first-month offers as low as £79, and £170 to £269 a month at the 25 mg maintenance dose. Slinic lists its own fixed prices at £99 for 1.5 mg, £119 for 4 mg, £135 for 9 mg, and £179 for 25 mg.

A price comparison needs two labels: provider and dose level. A starting price does not show what month four may cost once the 25 mg maintenance level becomes relevant. It also does not show whether the provider has that higher strength in stock on the day you check.

Treat these listed prices as a dated snapshot rather than a national tariff. They are public examples from regulated sellers, checked on July 13, 2026. They are not NHS access, reimbursement, or a guaranteed long-term monthly cost.

Why NHS access remains separate

The MHRA approval announcement for Wegovy tablets says the product is approved in the UK but is not currently available via the NHS. The BMJ note on private UK Wegovy pill access says NHS access still needs NICE evaluation for cost effectiveness. Retail launch coverage should not be read as NHS rollout.

The public NHS pages show the same split. The NHS semaglutide medicine page and the NHS England Wegovy specialist-service page still frame obesity treatment around specialist services and weekly semaglutide injections. The tablet can be available privately while the NHS pathway still uses older public wording.

NICE also matters in two different ways. NICE TA875 covers semaglutide for managing overweight and obesity, while NICE TA1152 covers semaglutide for reducing major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. Neither guidance page should be read as proof that the newly launched tablet can already be prescribed through every NHS route a patient may imagine.

What to check before switching from injections

The MHRA approval announcement for Wegovy tablets and the Wegovy 1.5 mg tablets SmPC both say that patients on private semaglutide injection 2.4 mg once weekly can transition to 25 mg tablets and start one week after the last injection. That rule does not answer cost, routine fit, or side-effect questions.

Anyone comparing pill against pen should look at four numbers together: the likely maintenance dose, the monthly price at that dose, the discipline of the daily timing routine, and the side-effect pattern they have already had on semaglutide. A tablet can feel simpler while still demanding more day-to-day attention than a weekly pen.

If you are planning a consultation, bring the exact injection strength, the last dose date, what mornings actually look like in your routine, and whether you want a record in the Wegovy pill tracker or GLP-1 tracker from day one. Those details usually tell the clinician more than a generic statement that a pill sounds easier.